The Experts below are selected from a list of 315 Experts worldwide ranked by ideXlab platform
Nigel P. Shankley - One of the best experts on this subject based on the ideXlab platform.
-
retracted obestatin reduces food intake and suppresses Body Weight Gain in rodents
Biochemical and Biophysical Research Communications, 2007Co-Authors: Guy Lagaud, Auzon Acena, Magda F Morton, Terrance D Barrett, Andy Young, Nigel P. ShankleyAbstract:Obestatin was recently described as a bioactive peptide encoded for by the same gene as ghrelin but with opposite actions on food intake. Although some groups have confirmed these findings others find no effect. We investigated the effect of obestatin on feeding in rodents over a wide range of doses. Acute administration of obestatin inhibited feeding at doses of 10-100 nmol/kg i.p. in mice and 100-300 nmol/kg i.p. in lean and Zucker fatty rats. Interestingly, the dose-response relationship was U-shaped such that both low and high doses were without effect in either species. Treatment of mice with obestatin over a 7-day period decreased Body Weight Gain and food consumption. Overall, obestatin suppressed food intake and Body Weight Gain in rodent and an unusual dose-response relationship was found. These findings may explain the difficulties in reproducing the effects of obestatin on feeding reported by some groups.
Guy Lagaud - One of the best experts on this subject based on the ideXlab platform.
-
retracted obestatin reduces food intake and suppresses Body Weight Gain in rodents
Biochemical and Biophysical Research Communications, 2007Co-Authors: Guy Lagaud, Auzon Acena, Magda F Morton, Terrance D Barrett, Andy Young, Nigel P. ShankleyAbstract:Obestatin was recently described as a bioactive peptide encoded for by the same gene as ghrelin but with opposite actions on food intake. Although some groups have confirmed these findings others find no effect. We investigated the effect of obestatin on feeding in rodents over a wide range of doses. Acute administration of obestatin inhibited feeding at doses of 10-100 nmol/kg i.p. in mice and 100-300 nmol/kg i.p. in lean and Zucker fatty rats. Interestingly, the dose-response relationship was U-shaped such that both low and high doses were without effect in either species. Treatment of mice with obestatin over a 7-day period decreased Body Weight Gain and food consumption. Overall, obestatin suppressed food intake and Body Weight Gain in rodent and an unusual dose-response relationship was found. These findings may explain the difficulties in reproducing the effects of obestatin on feeding reported by some groups.
Daniele Piomelli - One of the best experts on this subject based on the ideXlab platform.
-
synthesis and characterization of a peripherally restricted cb1 cannabinoid antagonist urb447 that reduces feeding and Body Weight Gain in mice
Bioorganic & Medicinal Chemistry Letters, 2009Co-Authors: Jesse Loverme, Andrea Duranti, Andrea Tontini, Gilberto Spadoni, Silvia Rivara, Nephi Stella, Cong Xu, Giorgio Tarzia, Daniele PiomelliAbstract:Cannabinoid CB1 receptor antagonists reduce Body Weight in rodents and humans, but their clinical utility as anti-obesity agents is limited by centrally mediated side effects. Here, we describe the first mixed CB1 antagonist/CB2 agonist, URB447 ([4-amino-1-(4-chlorobenzyl)-2-methyl-5-phenyl-1H-pyrrol-3-yl](phenyl)methanone), which lowers food intake and Body-Weight Gain in mice without entering the brain or antagonizing central CB1-dependent responses. URB447 may provide a useful pharmacological tool for investigating the cannabinoid system, and might serve as a starting point for developing clinically viable CB1 antagonists devoid of central side effects.
Masato Kasuga - One of the best experts on this subject based on the ideXlab platform.
-
antagonism of ghrelin receptor reduces food intake and Body Weight Gain in mice
Gut, 2003Co-Authors: Akihiro Asakawa, Akio Inui, Toshihiro Kaga, Goro Katsuura, Mineko Fujimiya, Masayuki A Fujino, Masato KasugaAbstract:Background and aims: Ghrelin, an endogenous ligand for growth hormone secretagogue receptor (GHS-R), is an appetite stimulatory signal from the stomach with structural resemblance to motilin. We examined the effects of the gastric peptide ghrelin and GHS-R antagonists on energy balance and glycaemic control in mice. Materials and methods: Body Weight, fat mass, glucose, insulin, and gene expression of leptin, adiponectin, and resistin in white adipose tissue (WAT) were measured after repeated administrations of ghrelin under a high fat diet. Gastric ghrelin gene expression was assessed by northern blot analysis. Energy intake and gastric emptying were measured after administration of GHS-R antagonists. Repeated administration of GHS-R antagonist was continued for six days in ob/ob obese mice. Results: Ghrelin induced remarkable adiposity and worsened glycaemic control under a high fat diet. Pair feeding inhibited this effect. Ghrelin elevated leptin mRNA expression and reduced resistin mRNA expression. Gastric ghrelin mRNA expression during fasting was increased by a high fat diet. GHS-R antagonists decreased energy intake in lean mice, in mice with diet induced obesity, and in ob/ob obese mice; it also reduced the rate of gastric emptying. Repeated administration of GHS-R antagonist decreased Body Weight Gain and improved glycaemic control in ob/ob obese mice. Conclusions: Ghrelin appears to be closely related to excess Weight Gain, adiposity, and insulin resistance, particularly under a high fat diet and in the dynamic stage. Gastric peptide ghrelin and GHS-R may be promising therapeutic targets not only for anorexia-cachexia but also for obesity and type 2 diabetes, which are becoming increasingly prevalent worldwide.
Stephen R Bloom - One of the best experts on this subject based on the ideXlab platform.
-
peripheral oxyntomodulin reduces food intake and Body Weight Gain in rats
Endocrinology, 2004Co-Authors: C L Dakin, C J Small, Rachel L Batterham, Nicola M Neary, Mark Cohen, Michael Patterson, Mohammad A Ghatei, Stephen R BloomAbstract:Oxyntomodulin (OXM) is a circulating gut hormone released post prandially from cells of the gastrointestinal mucosa. Given intracerebroventricularly to rats, it inhibits food intake and promotes Weight loss. Here we report that peripheral (ip) administration of OXM dose-dependently inhibited both fast-induced and dark-phase food intake without delaying gastric emptying. Peripheral OXM administration also inhibited fasting plasma ghrelin. In addition, there was a significant increase in c-fos immunoreactivity, a marker of neuronal activation, in the arcuate nucleus (ARC). OXM injected directly into the ARC caused a potent and sustained reduction in refeeding after a fast. The anorectic actions of ip OXM were blocked by prior intra-ARC administration of the glucagonlike peptide-1 (GLP-1) receptor antagonist, exendin9 –39, suggesting that the ARC, lacking a complete blood-brain barrier, could be a potential site of action for circulating OXM. The actions of ip GLP-1, however, were not blocked by prior intraARC administration of exendin9 –39, indicating the potential existence of different OXM and GLP-1 pathways. Seven-day ip administration of OXM caused a reduction in the rate of Body Weight Gain and adiposity. Circulating OXM may have a role in the regulation of food intake and Body Weight. (Endocrinology 145: 2687–2695, 2004)